Intermune, Inc.

Other

Stefania Vallese

Leonid Beigelman

Scott D Seiwert

Vladimir Serebryany

Tao Hu

Karl Kossen

Donald Ruhrmund

Luca Francesco Mario Raveglia

Ivana Bianchi

Luca Francesco Raveglia

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. Mederski et al., Tetrahedron (1999), 55(44), 12757-12770.* Azuma et al., 'A placebo control and double blind phase II clinical study of pirfenidone in patients with idiopathic pulmonary fibrosis in Japan', Am J Respir Crit Care Med., 165:A729 (2002). Badger, et al., 'Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function', J. Pharmacol. Exp. Ther. 279:1453-61 (1996).

Compounds and methods for treating inflammatory and fibrotic disorders

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.

Growing community of inventors

Cardano al Campo, Italy

Stefania Vallese